Guidelines

The preferred choice

Highest rated CDK4/6i in ABC & highest rating in EBC. ^(1-3)

KISQALI: Trusted by physicians. Proven in patients. ^(1–4)
International ABC guidelines recognise the powerful efficacy of KISQALI across a broad patient population. ^(2,3,5)

NCCN

Only Category 1 -rated
CDK4/6i with both AI and fulvestrant⁽¹⁾

ESMO-MCBS

Highest-rated
CDK4/6i in class⁽²⁾

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Abbreviations

ABC, advanced breast cancer; AI, aromatase inhibitor; CDK4/6i, cyclin-dependent kinase 4 and 6 inhibitor; ESMO, European Society for Medical Oncology; HR+, hormone receptor-positive; HER2–, human epidermal growth factor receptor 2-negative; MCBS, Magnitude of Clinical Benefit Scale; NCCN, National Comprehensive Cancer Network.

References

KISQALI (ribociclib), Summary of Product Characteristics.
NCCN Guidelines®. Breast Cancer, Version 3.2025.
ESMO. ESMO-MCBS scorecards.
Novartis Internal Volume Sales Data, 2024.
Cardoso F, et al. Breast. 2024;76:103756.

NCCN consensus

NCCN® recommends KISQALI as a Category 1 preferred treatment option in both ABC and EBC. ⁽¹⁾

In phase 3 randomised controlled trials, KISQALI + ET has shown OS benefit in the first-line setting compared with ET alone. ⁽¹⁾

Table comparing treatment recommendations for HR+/HER2- metastatic breast cancer among CDK4/6 inhibitors. KISQALI is Category 1 with both aromatase inhibitor and fulvestrant, Abemaciclib is Category 2A with AI and Category 1 with fulvestrant, Palbociclib is Category 2A with both.

* Based upon the high-level evidence, there is uniform consensus that the intervention is appropriate. ⁽¹⁾
† Based upon low-level evidence, there is uniform consensus that the intervention is appropriate. ⁽¹⁾

Abbreviations

ABC, advanced breast cancer; AI, aromatase inhibitor; CDK4/6i, cyclin-dependent kinase 4 and 6 inhibitor; ET, endocrine therapy; HER2–, human epidermal growth factor negative; HR+, hormone receptor positive; NCCN, National Comprehensive Cancer Network; OS, overall survival.

References

NCCN Guidelines®. Breast Cancer, Version 3.2025.

ESMO-MCBS

KISQALI has the highest ESMO-MCBS scores (green “4” for ABC) among CDK4/6i.^(1-7)

Choose KISQALI: the only CDK4/6i with the highest clinical benefit scores among the CDK4/6i class on the ESMO-MCBS, due to its consistent and proven OS benefits. ^(1-7)

ESMO-MCBS scorecards in HR+/HER2- ABC
CDK4/6i	Combination agent	Study name	Score	Outcome achieved
KISQALI	AI	MONALEESA-2⁽¹⁾	4	OS
	Fulvestrant	MONALEESA-3⁽²⁾	4	OS
	ET	MONALEESA-7⁽³⁾*	4	OS
Abemaciclib	AI	MONARCH-3⁽⁴⁾*	1	PFS
Abemaciclib	Fulvestrant	MONARCH-2⁽⁵⁾*	3	OS
Palbociclib	AI	PALOMA-2⁽⁶⁾	2	PFS
Palbociclib	Fulvestrant	PALOMA-3⁽⁷⁾	4	PFS

← Slide to view more →

Evaluated outcome OS (comprative studies)

Evaluated outcome PFS (comprative studies)

* Scorecards updated on the 22.08.2025. With permission from ESMO.

Abbreviations

ABC, advanced breast cancer; AI, aromatase inhibitor; CDK4/6i, cyclin-dependent kinase 4 and 6 inhibitor; ESMO, European Society for Medical Oncology; ET, endocrine therapy; HR+/HER2–, hormone receptor-positive/human epidermal growth factor receptor 2-negative; MCBS, Magnitude of Clinical Benefit Scale; OS, overall survival; PFS, progression-free survival.

References

Clinical Trial Information

MONALEESA-2 ClinicalTrials.gov number, NCT01958021
MONALEESA-3 ClinicalTrials.gov number, NCT02422615 MONALEESA-7 ClinicalTrials.gov number, NCT02278120
MONARCH-2 ClinicalTrials.gov number, NCT02107703 MONARCH-3 ClinicalTrials.gov number, NCT02246621
PALOMA-2 ClinicalTrials.gov number, NCT01740427
PALOMA-3 ClinicalTrials.gov number, NCT05388669
Studies available online at: https://clinicaltrials.gov

Guidelines

The preferred choice

Highest rated CDK4/6i in ABC & highest rating in EBC. (1-3)

NCCN

ESMO-MCBS

NCCN consensus

NCCN® recommends KISQALI as a Category 1 preferred treatment option in both ABC and EBC. (1)

ESMO-MCBS

KISQALI has the highest ESMO-MCBS scores (green “4” for ABC) among CDK4/6i.(1-7)

Highest rated CDK4/6i in ABC & highest rating in EBC. ^(1-3)

NCCN® recommends KISQALI as a Category 1 preferred treatment option in both ABC and EBC. ⁽¹⁾

KISQALI has the highest ESMO-MCBS scores (green “4” for ABC) among CDK4/6i.^(1-7)